

BAB 8**DAFTAR PUSTAKA**

1. World Health Organization. World health statistics 2012. Tersedia di :
http://www.who.int/gho/publications/world_health_statistics/2012/en/.
Diakses pada 5 September 2015.
2. Heron M, Hoyert S, Murphy J, Kochanek K, Tejada-Vera B. Deaths: final data for 2006. Division of Vital Statistics, Centers for Disease Control and Prevention. *Natl Vital Stat Rep.* 2009;57(14): 1-134.
3. Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N. Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systemic review and meta-analysis. *Critical Care.* 2015; 19(63).
4. Instalasi Rekam Medik RSUD. Dr. Soetomo Surabaya. Data diakses tanggal 1 Oktober 2015.
5. Mettler J, Simcock M, Sendi P, Widmer AF, Bingisser R, Battegay M, et al. Empirical use of antibiotics and adjustment of empirical antibiotic therapies in a university hospital: a prospective observational study. *BMC Infectious Disease.* 2007; 7:21.
6. Swanson JM, Wells DL. Empirical antibiotic therapy for ventilator-associated pneumonia. *Antibiotics.* 2013; 2: 339-351.
7. Hogerzeil HV. Promoting rational prescribing: an international perspective. *Br. J. Clin Pharmac.* 1995; 39:1-6.

8. Hadi U, Duerink DO, Lestari ES, Nagelkerke NJ, Keuter M, Huis D, et al. Audit of antibiotic prescribing in two governmental teaching hospitals in Indonesia. *Clin Microbiol Infect*. 2008; 14: 698-707.
9. Claridge JA, Pang P, Leukhardt WH, Golob JF, Carter J, Fadlalla AM. Critical analysis of empiric antibiotic utilization: establishing benchmarks. *Surgical Infections*. 2010; 11(2): 125-131.
10. Hecker MT, Aron DC, Patel NP, Lehmann MK, Donskey CJ. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity. *Arch Intern Med*. 2003; 163(8): 972-978.
11. Kuppala VS, Meinen-Deer J, Morrow AL, Schibler KR. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. *J Pediatr*. 2011; 159(5): 720-725.
12. Barbut F, Petit JC. Epidemiology of *Clostridium difficile* associated infections. *Clin Microbiol Infect*. 2001; 7: 405-510.
13. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. *Intensive Care Med*. 2013; 39: 165-228.
14. Ansari F. Use of systemic anti-infective agents in Iran during 1997-1998. *Eur J Clin Pharmacol*. 2001; 57: 547-551

15. Chukwuani CM, Onifade M, Sumonu K. Survey of drug practices and antibiotic prescribing at a general hospital in Nigeria. *Pharm World Sci.* 2002; 24: 188-195.
16. Hu S, Liu X, Peng Y. Assessment of antibiotic prescription in hospitalized patients at a Chinese university hospital. *J Infect.* 2003; 48: 117-118.
17. Gyssens IC, Geerligs EJ, Dony JMJ, Van der Vliet JA, Van Kapen A, Van den Broek PJ. Optimising antimicrobial drug use in surgery : an intervention study in a Dutch university hospital. *Journal of Antimicrobial Chemotherapy.* 1996; 38: 1001-1012.
18. Van Der Meer JWM, Gyssens IC. Quality of antimicrobial drug prescription in hospital. *Clin Microbiol Infect.* 2001; 7(6): 12-15.
19. Speert DP. Antimicrobial resistance : implications for therapy of infections with common childhood pathogens. *Can J Infect Dis.* 1996; 7(3) : 169-173.
20. Leekha S, Terrek CL, Edson RS. General principles of antimicrobial therapy. *Mayo Clin Proc.* 2011; 86(2): 156-167.
21. Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. *Infect Dis Clin North Am.* 2009 Desember; 23(4).
22. Varley AJ, Sule J, Absalom AR. Principles of antibiotic therapy. *Continuing Education in Anaesthesia, Critical Care & Pain.* 2009; 9(6): 184-188.
23. McDonagh DL editor. 2015. Antimicrobial agents. Tersedia di: <http://www.openanaesthesia.org/antimicrobial-agents/> (Diakses 1 September 2015).

24. Guglielmo BJ. 2014. Anti-Infective Chemotherapeutic & Antibiotic Agents chapter e1. Tersedia di : <http://accessmedicine.mhmedical.com/content.aspx?bookid=330§ionid=44291033>(Diakses 1 September 2015)
25. Ritter JM, Lewis LD, Mant T, Ferro A. A textbook of clinical pharmacology and therapeutics edisi kelima. London: Hodder Arnold; 2008.
26. Grabe M, Bjerklund-Johansen TE, Botto H, Cek M, Naber KG, Tenke P, et al. Guidelines on urological infections. The Netherlands: European Association of Urology; 2013.
27. Clinical and Laboratory Standards Institute. Performance standars for antimicrobial susceptibility testing; twenty-fourth informational supplement. Pennsylvania, USA. 2014; 34(1)
28. Saha R, Das S, Chatterjee R, Kaur I. The pathophysiology of septic shock. International Journal of Pharma and Bio Sciences. 2010; 1(2).
29. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34(6): 1589-1596.
30. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE. Initiation of inappropriate antimicrobial therapy in a fivefold reduction of survival in human septic shock. Chest. 2009;136: 1237-1248.

31. Khasawneh FA, Karim A, Mahmood T, Ahmed S, Jaffri SF, Mehmood M. Safety and feasibility of de-escalation in bacteremic pneumonia. *Infection and Drug Resistance*. 2014; 7: 177-182.
32. Garnacho-Montero Gutierrez-Pizarra A, Escosca-Ortega A, Corcia-Palomo Y, Fernandez-Delgado E, Herrera-Melero I. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. *Intensive Care Med*. 2014; 40(1): 32-40.
33. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med*. 2005; 171: 388-416.
34. Kumar A, Zarychanski R, Light B, Parriilo J, Maki D, Simon D. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis*. *Crit Care Med*. 2010; 38(9): 1773-1785.
35. Wagenlehner F, Lichtenstern C, Rolfes C, Mayer K, Uhle F, Weidner W. Diagnosis and management of urosepsis. *International Journal of Urology*. 2013; 20: 963-970.
36. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell D, Dean NC, et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. *Clinical infectious diseases*. 2007; 44(2): S27-72
37. Eckmann C, Dryden M, Montravers P, Kozlov R, Sganga G. Antimicrobial treatment of “complicated” intra-abdominal infections and the new IDSA

- guidelines – a commentary and an alternative european approach according to clinical definitions. *European Journal Of Medical Research*. 2011; 16: 115-126.
38. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM. Practice guidelines for the management of bacterial meningitis. *Clinical Infectious Diseases*. 2004; 39: 1267-1284.
39. Burleigh K, Cameron S, German G, Harris-Eze A, Harrison E, Irvine M. 2014. Skin and soft tissue infection empiric treatment guidelines. Tersedia di http://www.gov.pe.ca/photos/original/hpei_skintissue.pdf (Diakses 17 September 2015).
40. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. *JAMA*. 2009; 302: 2323-9.
41. Angus DC, Linde-Zwirbie WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med*. 2001; 29(7):1303-1309.
42. Pollock AA, Tee PE, Patel IH, Spicehandler J, Simberkoff MS, Rahal JJ. Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults. *Antimicrobial Agents and Chemotherapy*. 1982; 22(5): 816-823.
43. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979-2000. *N Engl J Med*. 2003; 348: 1546-54.

44. Guentzel M, Baron S (editor). 1996. Medical microbiology edisi 4. Chapter 26. Escherichia, Klebsiella, Enterobacter, Citrobacter and Proteus. University of Texas. Tersedia di <http://www.ncbi.nlm.nih.gov/books/NBK8035/>. (Diakses pada 2 Desember 2015).
45. Angus DC, Van Der Poll T. Severe sepsis and septic shock. *N Engl J Med*. 2013; 369: 840-51.
46. Phua J, Ngerng WJ, See KC, Tay CK, Kiong T, Lim HF et al. Characteristics and outcomes of culture-negative versus culture-positive severe sepsis. *Critical Care*. 2013; 17:R202.
47. Martin CM, Priestap F, Fisher H, Fowler RA, Heyland DK, Keenan SP et al. A prospective, observational registry of patients with severe sepsis: the Canadian Sepsis Treatment and Response Registry. *Crit Care Med*. 2009; 37: 81-88.
48. Blanco J, Muriel-Bombin A, Sagredo V, Taboada F, Gandia F, Tamayo L et al. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicenter study. *Crit Care*. 2008, 12:R158.
49. Brun-Buisson C, Medhaka P, Pinton P, Vallet B: EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. *Intensive Care Med*. 2004; 30: 580-588.
50. Ntusi N, Aubin L, Oliver S, Whitelaw A, Mendelson M. Guideline for the optimal use of blood cultures. *SAMJ*. 2010; 100(12): 839-843.